Altium Capital Management LLC Invests $1.52 Million in ProQR Therapeutics (NASDAQ:PRQR)

Altium Capital Management LLC acquired a new stake in shares of ProQR Therapeutics (NASDAQ:PRQR) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 575,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,524,000.

A number of other institutional investors have also modified their holdings of PRQR. Affinity Asset Advisors LLC bought a new position in ProQR Therapeutics in the fourth quarter worth about $7,486,000. M&T Bank Corp acquired a new stake in shares of ProQR Therapeutics during the 4th quarter worth approximately $330,000. BNP Paribas Financial Markets lifted its holdings in shares of ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 7,300 shares during the last quarter. Virtu Financial LLC acquired a new position in ProQR Therapeutics during the 4th quarter valued at approximately $83,000. Finally, Platinum Investment Management Ltd. bought a new position in ProQR Therapeutics during the 4th quarter worth $4,076,000. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Stock Performance

Shares of NASDAQ:PRQR opened at $1.14 on Friday. The company has a 50 day moving average of $1.76 and a 200-day moving average of $2.52. The firm has a market cap of $119.94 million, a P/E ratio of -3.56 and a beta of 0.25. ProQR Therapeutics has a twelve month low of $1.07 and a twelve month high of $4.62.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PRQR. Oppenheimer started coverage on ProQR Therapeutics in a research note on Friday, January 10th. They issued an “outperform” rating and a $15.00 target price on the stock. Chardan Capital reiterated a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research report on Friday, March 14th. HC Wainwright upped their target price on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, March 14th. Finally, Citigroup raised ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price target on the stock in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

ProQR Therapeutics Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).